Jiangsu NHWA Pharma and its Israeli partner, D-Pharm Ltd., were approved to begin China clinical trials of their epilepsy treatment, DP-VPA. The drug was granted China Fast-Track status last year. Because DP-VPA has completed Phase II trials outside of China, NHWA will initially complete a bridging safety study and then conduct a large dose-ranging Phase IIb China trial among epilepsy patients. NHWA in-licensed greater China rights to the drug from D-Pharm in 2011.
Help employers find you! Check out all the jobs and post your resume.
